Issued on behalf of BioVaxys Technology Corp. VANCOUVER – USA News Group – According to the World Health...
The drug and biotech sector saw a strong first half of 2024, driven by an increase in mergers and acquisitions (M&A), robust earnings, and pipeline and regulatory successes. The Zacks Large Cap Pharmaceuticals...
/Biogen%20Inc%20magnified-by%20Casimiro%20PT%20via%20Shutterstock.jpg)
Biogen has recently lagged behind the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on the stock's long-term growth potential.
Roche RHHBY announced that the European Medicines Agency has approved a prefilled syringe (PFS) of the ophthalmology drug Vabysmo (faricimab).The regulatory body approved Vabysmo PFS for use in the treatment...
Investors should consider these three penny stocks for their solid upside potential, even after this year's rally.
The going has been pretty good for Bristol Myers BMY in the past six months. Shares of this biotech giant have rallied 36.4% in the said timeframe against the industry’s decline of 1.8%. The stock has...
Eli Lilly and Company LLY announced that its board of directors approved a new $15 billion share buyback plan. The earlier $5 billion stock repurchase plan ended in the fourth quarter of 2024.The board...
Monday, December 9, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and...
GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD) treatment for...
AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license application (sBLA) seeking expanded use of its blockbuster drug, Imfinzi (durvalumab),...